Gapping up
In reaction to earnings/guidance:
- BHP +7.5%, CEVA +4.5%, TRTN +3.8%, RXN +3.8%, VMC +3.7%, LPX +3.6%, GEO +3.3%, JELD +2.8%, NBEV +2.8% (also entered into a definitive agreement with investors to purchase 14.6 million shares of common stock in a private placement with purchase price for the shares of common stock at $3.96 per share) CTAS +2.2%, AAP +1.9%, AN +1.7%, ARD +1.7%, CVS +1.6%, HP +1.5%, LBTYA +1.3%, ZTS +1.3%, ACM +1.3%, MEDP +1.1%, IAA +1%
Select metals/mining stocks trading higher:
- RIO +5.5%, FCX +4.5%, AG +2.2%, PAAS +2%, SLV +0.8%
Select oil/gas related names showing strength:
- BP +6.5%, RDS.A +4.5%, MRO +4.1%, SLB +2.9%, HAL +2.9%, XOM +2.6%, XLE +2.4%, PSX +1.6%
Other news:
- GTHX +32.1% (receives FDA approval for COSELA)
- SESN +22.5% (FDA accepted for filing the Company's Biologics License Application for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer, and granted the application Priority Review)
- IMAX +14.8% (reports record-breaking Chinese New Year opening weekend with $25 million, up 45% from previous best)
- STPK +14.6% (Jim Cramer came out very positive)
- AACQ +14.5% (M&A rumor of possible transaction with Origin Materials)
- STIC +13.1% (Northern Star Acquisition Corp.'s merger partner, Barkbox, Inc, announces 3Q21 guidance)
- PDAC +9.7% (Li-Cycle, North America's largest lithium-ion battery resource recycling company, to list on NYSE through transaction with Peridot Acquisition Corp)
- BWA +7.8% (acquires AKASOL AG for €727 mln)
- DPW +7.8% (buys 9.91% equity interest in SilverSun Technologies)
- BFLY +6.3% (closes transaction; sees 2020 full-year revenue of at least $45 million)
- SWAV +6.3% (announces that the company's sonic pressure wave therapy received Pre-Market Approval for severely calcified coronary artery disease from the U.S. Food and Drug Administration)
- IDEX +5.6% (files for 12,589,350 share common stock offering by selling shareholders)
- CLSD +5.2% (details presentation that highlighted several of the key attributes of axitinib and Clearside's suprachoroidal delivery of the agent)
- MT +4% (to commence share buyback program)
- MILE +3.3% (files for 7,846,666 share common stock offering; also files for 50,871,441 share common stock offering by selling shareholders)
- EXEL +2.5% (Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors)
- LUV +2.4% (reports operational results)
- TPR +2.1% (files for mixed securities shelf offering, no amount given)
- IIVI +2.1% (Coherent (COHR) to engage in discussions with II-VI (IIVI))
Analyst comments:
- PLAN +5.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ALB +3.4% (upgraded to Buy from Hold at Deutsche Bank)
- WISH +1.8% (upgraded to Buy from Hold at Loop Capital)